The Anticancer Journey of Liquiritin: Insights into Its Mechanisms and Therapeutic Prospects.

Bhat, AA; Moglad, E; Afzal, M; Agrawal, N; Thapa, R; Almalki, WH; Kazmi, I; Alzarea, SI; Ali, H; Sharma, S; Singh, SK; Dua, K; Gupta, G

The Anticancer Journey of Liquiritin: Insights into Its Mechanisms and Therapeutic Prospects.

Bhat, AA Moglad, E Afzal, M Agrawal, N Thapa, R Almalki, WH Kazmi, I Alzarea, SI Ali, H Sharma, S Singh, SK Dua, K

Gupta, G

Permalink

Publisher:: Bentham Science Publishers Ltd.
Publication Type:: Journal Article
Citation:: Curr Med Chem, 2024, 31
Issue Date:: 2024-08-19

Embargoed

	Filename	Description	Size
	Anticancer_Liquiritin_BMS-CMC-2024-156.pdf	Published version	1.35 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Embargoed
Open Access

This item is currently unavailable due to the publisher's embargo.

The embargo period expires on 19 Aug 2025

Full metadata record

Field	Value	Language
dc.contributor.author	Bhat, AA
dc.contributor.author	Moglad, E
dc.contributor.author	Afzal, M
dc.contributor.author	Agrawal, N
dc.contributor.author	Thapa, R
dc.contributor.author	Almalki, WH
dc.contributor.author	Kazmi, I
dc.contributor.author	Alzarea, SI
dc.contributor.author	Ali, H
dc.contributor.author	Sharma, S
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Gupta, G
dc.date.accessioned	2024-09-04T02:22:04Z
dc.date.available	2024-06-25
dc.date.available	2024-09-04T02:22:04Z
dc.date.issued	2024-08-19
dc.identifier.citation	Curr Med Chem, 2024, 31
dc.identifier.issn	0929-8673
dc.identifier.issn	1875-533X
dc.identifier.uri	http://hdl.handle.net/10453/180612
dc.description.abstract	Liquiritin (LIQ), a bioactive flavonoid from Glycyrrhiza species, has shown significant potential in cancer therapy. LIQ exhibits potent inhibitory effects on various cancer cell types, including breast, lung, liver, and colon cancers, while demonstrating low toxicity towards healthy cells. Its anticancer mechanisms include inducing cell cycle arrest, promoting apoptosis, and modulating inflammation-related pathways. Additionally, LIQ impedes angiogenesis and enhances the efficacy of conventional chemotherapies through sensitization and synergistic effects with other natural compounds and targeted therapies. These multifaceted actions highlight LIQ as a promising candidate for further development as an anticancer agent. This abstract provides an overview of LIQ's chemistry, biological effects, and underlying mechanisms.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartof	Curr Med Chem
dc.relation.isbasedon	10.2174/0109298673315699240805111122
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.subject	0304 Medicinal and Biomolecular Chemistry, 0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	3404 Medicinal and biomolecular chemistry
dc.title	The Anticancer Journey of Liquiritin: Insights into Its Mechanisms and Therapeutic Prospects.
dc.type	Journal Article
utslib.citation.volume	31
utslib.location.activity	United Arab Emirates
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/All Manual Groups
pubs.organisational-group	University of Technology Sydney/All Manual Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/All Manual Groups/Centre for Inflammation (CFI)/Associate Member
utslib.copyright.status	embargoed	*
utslib.copyright.embargo	2025-08-19T00:00:00+1000Z
dc.date.updated	2024-09-04T02:22:02Z
pubs.publication-status	Published online
pubs.volume	31

Abstract:

Liquiritin (LIQ), a bioactive flavonoid from Glycyrrhiza species, has shown significant potential in cancer therapy. LIQ exhibits potent inhibitory effects on various cancer cell types, including breast, lung, liver, and colon cancers, while demonstrating low toxicity towards healthy cells. Its anticancer mechanisms include inducing cell cycle arrest, promoting apoptosis, and modulating inflammation-related pathways. Additionally, LIQ impedes angiogenesis and enhances the efficacy of conventional chemotherapies through sensitization and synergistic effects with other natural compounds and targeted therapies. These multifaceted actions highlight LIQ as a promising candidate for further development as an anticancer agent. This abstract provides an overview of LIQ's chemistry, biological effects, and underlying mechanisms.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/180612